Eurofins Signs an Exclusive Agreement to Acquire the Biomnis Group
2015年6月22日 - 3:07PM
ビジネスワイヤ(英語)
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), the global leader in
bio-analytical testing, and one of the world leaders in genomic
services, announces that it has signed an exclusive agreement with
Financière Bio Alfras SAS to acquire the Biomnis Group for
approximately EUR 220m. The contemplated transaction is expected to
be completed over the summer, subject to customary closing
conditions including regulatory approvals and employees’
representatives’ information and consultation.
Biomnis is one of the main independent specialty/esoteric
diagnostic testing service providers in France and Ireland. It is
one of the largest independent laboratories in Europe focusing on
specialty diagnostic testing, with a strong reputation in many
areas including infectious diseases, supported by its renowned
competence in molecular biology and cytogenetics. With over 100
years of laboratory testing excellence, Biomnis developed its
expertise in high-complexity testing over the last 15 years through
investments in state-of-the-art equipment and selected
acquisitions. The company employs about 1,200 staff, provides its
services in more than 40 countries and has generated over EUR 220m
revenues in 2014, three-quarters of which from specialty
diagnostics services. Following the recent Biomnis restructuring,
Eurofins expects that the company’s EBITDA margin should
progressively expand from the current low double-digit level
towards industry standards and Eurofins’ objective over the next
few years.
Biomnis has 2 main sites in France (Lyon and Paris) and 1 site
in Ireland. In addition, it owns 26 medical biology sites across
France that run less complex tests, and are also channels for the
specialty diagnostic tests which are then sent on to the
laboratories in Paris or Lyon. The company is also active in
clinical trials for the pharmaceutical industry, and in forensic
testing. Biomnis serves mainly institutional clients including
hospitals, pharmaceutical companies and a large number of other
third party medical biology laboratories which outsource the more
complex tests to Biomnis. Given the ongoing consolidation in the
clinical testing sector in Europe, and specifically in France, the
company is well-positioned to leverage and strengthen its footprint
in the specialty diagnostic testing sector.
Should the contemplated transaction come to closing, the
addition of Biomnis to the Eurofins network would strengthen the
Group’s pharmaceutical and genomic service offering, and
consolidate its growing presence in the specialty diagnostic
testing sector, following the acquisition of ViraCor, Boston Heart
and Diatherix in the US. Furthermore, Biomnis should provide the
Group a strong platform in Europe on which to deploy its technical
know-how in specialty clinical diagnostic testing, and strengthen
its position in this sector in France, in addition to the
acquisition of BioAccess. Eurofins’ renowned capabilities in
genomic testing, and its international presence, should support
Biomnis in developing its portfolio of tests and services, as well
as consolidate their client reach.
Through Biomnis, Eurofins intends to closely collaborate with
the French health authorities, the local medical laboratories
industry, as well as public and private hospitals, to support them
in fulfilling their objective of ensuring world-class patient care
in France. In the context of this partnership with the French
Medical Biology profession, should this acquisition proceed
successfully, Eurofins intends to offer other selected participants
in the local clinical biology testing market in France the option
to co-invest in Biomnis specialty laboratory.
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food and
pharmaceutical products testing. It is also number one in the world
in the field of environmental laboratory services and one of the
global market leaders in agroscience, genomics, discovery
pharmacology and central laboratory services.
With over 17,000 staff in more than 200 laboratories across 36
countries, Eurofins offers a portfolio of over 130,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150621005065/en/
Investor RelationsEurofins Scientific GroupPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 9 2024 まで 10 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 10 2023 まで 10 2024